天津久日新材料股份有限公司 独立董事关于第五届董事会第三次会议相关事项的独立意见 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司治理 准则》《上市公司独立董事规则》《上海证券交易所科创板股票上市规则》以及 《天津久日新材料股份有限公司章程》等有关规定,我们作为天津久日新材料股 份有限公司(以下简称公司)的独立董事,对 2023年8月18日召开的公司第五 届董事会第三次会议审议的《关于公司 2023年半年度募集资金存放与使用情况 的专项报告的议案》和《关于公司 2023年半年度计提资产减值准备的议案》发 表如下独立意见: 一、《关于公司 2023年半年度募集资金存放与使用情况的专项报告的议案》 的独立意见 经核查,我们认为:公司 2023年半年度募集资金存放与使用情况符合有关 法律、法规和《天津久目新材料股份有限公司募集资金管理制度》的相关规定。 《天津久日新材料股份有限公司 2023 年半年度募集资金存放与使用情况的专项 报告》真实、准确、完整的反映公司募集资金存放、使用、管理情况,不存在变 相改变募集资金用途的情形,不存在损害公司及股东,特别是中小股东利益的情 形。 张 弛 经核查,我们认为 ...

天津久日新材料股份有限公司 关于公司控股股东、实际控制人、董事长 提议公司回购股份的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 天津久日新材料股份有限公司（以下简称公司）董事会于 2023 年 8 月 17 日收 到公司控股股东、实际控制人、董事长赵国锋先生"关于使用部分超募资金以集中 竞价交易方式回购公司股份"的提议。具体内容如下： 证券代码：688199 证券简称：久日新材 公告编号：2023-049 一、提议人的基本情况及提议时间 1.提议人：公司控股股东、实际控制人、董事长赵国锋先生 2.提议时间：2023 年 8 月 17 日 二、提议人提议回购股份的原因和目的 赵国锋先生基于对公司未来持续发展的信心和对公司长期价值的合理判断，为 完善公司长效激励机制，充分调动公司员工的积极性，提高公司员工的凝聚力，同 时为了维护广大投资者利益，增强投资者对公司的投资信心，促进公司长期健康发 展，进一步建立公司、股东、核心骨干员工之间风险共担、利益共享的长效机制， 使各方更紧密地合力推进公司的长远、稳定、持续发展，建议 ...

证券代码：688199 证券简称：久日新材 天津久日新材料股份有限公司 2023 年第四次临时股东大会 会议资料 2023 年 8 月 天津久日新材料股份有限公司 2023 年第四次临时股东大会 目 录 1 一、天津久日新材料股份有限公司 2023 年第四次临时股东大会会议须知 二、天津久日新材料股份有限公司 2023 年第四次临时股东大会会议议程 三、天津久日新材料股份有限公司 2023 年第四次临时股东大会会议议案 议案一：《关于变更部分募集资金投资项目的议案》 议案二：《关于第五届董事会独立董事津贴标准的议案》 议案三：《关于第五届监事会监事津贴标准的议案》 天津久日新材料股份有限公司 2023 年第四次临时股东大会 天津久日新材料股份有限公司 2023 年第四次临时股东大会会议须知 为维护天津久日新材料股份有限公司（以下简称公司）全体股东的合法权益， 确保股东大会会议秩序和议事效率，保证股东大会的顺利召开，根据《中华人民 共和国公司法》《中华人民共和国证券法》《上市公司股东大会规则（2022 年 修订）》以及《天津久日新材料股份有限公司章程》和《天津久日新材料股份有 限公司股东大会议事规则》等相关规定 ...

裵埈範（BAE JUNBOM）先生，1970 年 5 月出生，韩国国籍，庆熙大学电子 工程学士。历任现代电子（现 SK 海力士）光学处理工程师，科莱恩韩国 IC 芯片 销售及技术支持，科莱恩 193nm 光刻胶项目组成员、研发部成员，安智韩国平板 显示器销售经理，安智中国新业务发展经理-FPD 及半导体、面板/光电市场部经 理，默克中国光刻胶市场部经理/面板项目部经理，默克韩国半导体项目国际 QA 专家，易美太公司研发部/首席研究员；2023 年 7 月，就职于公司，现任天津久 证券代码：688199 证券简称：久日新材 公告编号：2023-048 1 天津久日新材料股份有限公司 日半导体材料有限公司 QA&QC 总监。 关于新增认定核心技术人员的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 天津久日新材料股份有限公司（以下简称公司）为进一步提升在半导体化学 材料领域的创新能力和技术水平，加强研发团队实力，确保技术升级和研发目标 的实现，现根据公司实际情况并经管理层研究，结合任职履历、未来对公司研发 项目和业务发展 ...

Financial Performance - In 2022, the company achieved operating revenue of CNY 1,410,958,551.74, an increase of 12.66% year-on-year[4]. - The net profit attributable to shareholders was CNY 43,347,271.78, a decrease of 73.83% compared to the previous year[4]. - The company will not distribute profits for the 2022 fiscal year, opting to retain earnings for future investments and operational needs[13]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB, representing a year-over-year growth of 15%[28]. - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 10% to 1.32 billion RMB[28]. - The basic earnings per share fell by 73.86% to ¥0.40, down from ¥1.53 in 2021[30]. - The net profit attributable to shareholders after excluding non-recurring gains and losses was approximately ¥16.22 million, down 87.14% from ¥126.17 million in 2021[29]. - The company achieved a revenue of CNY 1,410,958,551.74 in 2022, representing a year-on-year increase of 12.66%[41]. - The net profit attributable to shareholders was CNY 43,347,271.78, a year-on-year decrease of 73.83%[41]. - The company reported a significant drop in sales volume of light initiators due to a weak end market, impacting overall performance[31]. Production Capacity and Expansion - The company has expanded its production capacity with the commissioning of a project in Inner Mongolia, which has an annual capacity of 9,250 tons of photoinitiators and intermediates[5]. - The company has established multiple modern production bases for photopolymer materials, including locations in Shandong, Hunan, Jiangsu, and Inner Mongolia[5]. - The company has initiated a project for producing 600 tons of photoresist-specific photoinitiators, which began trial production in October 2022[6]. - The company plans to strengthen its semiconductor chemical materials sector by advancing the planning and construction of a semiconductor photoresist production base[7]. - The company is investing in new production bases to enhance production capacity and meet growing market demands[51]. - The company has developed a large-scale production process for photoinitiators, demonstrating strong independent R&D capabilities[94]. - The company has optimized production processes and updated equipment at its Hunan and Shandong bases, improving production efficiency[44]. - The company has achieved a substantial increase in production capacity through the automation of traditional synthesis processes for photo-initiators 1173 and 184[71]. Research and Development - The company added 52 new patents during the reporting period, including 25 invention patents and 27 utility model patents, enhancing its innovation capabilities[42]. - Research and development expenses accounted for 5.99% of operating revenue, slightly up from 5.65% in 2021[30]. - The total R&D investment for the year was ¥84,524,096.49, representing a 19.45% increase compared to the previous year[79]. - The company has established a national enterprise technology center and a national postdoctoral research station, enhancing its R&D capabilities[91]. - The company is focusing on environmental innovation processes in its photoinitiator production, improving energy efficiency and sustainability[75]. - The company has developed new core technologies including "photo-sensitizer production technology" and "panel photoresist formulation technology" during the reporting period[69]. - The company is focusing on continuous innovation in new products and technologies, which is a core competitive advantage[90]. - The company has developed innovative production processes for its core products, significantly reducing raw material consumption and waste generation while enhancing safety[184]. Market Strategy and Challenges - The company continues to face challenges due to a significant decline in market demand and has implemented pricing strategies to maintain market share[11]. - The company aims to become a global leader in photopolymer materials, focusing on innovation and expansion in both the photopolymer and semiconductor industries[7]. - The company adopted a sales discount strategy to maintain market share, which contributed to a decline in revenue and gross profit[31]. - The competitive landscape remains challenging, with potential further declines in sales volume and prices for photoinitiators due to ongoing geopolitical tensions and economic uncertainties[123]. - The company is exposed to exchange rate risks due to a significant portion of revenue coming from exports, which could affect foreign exchange gains and losses[106]. - The company faces risks related to the potential loss of core technical personnel, which is critical for maintaining competitive advantage[112]. - The company is focusing on enhancing its product offerings and technological advancements to drive future growth[132]. Environmental and Sustainability Efforts - The company aims to reduce VOC emissions by 15% in line with environmental regulations[28]. - The UV curing technology is recognized for its environmental benefits, efficiency, and cost-effectiveness, aligning with global sustainability trends[54]. - The company is positioned to benefit from favorable industry policies promoting the use of eco-friendly materials and technologies[57]. - The company’s focus on energy-saving and emission-reduction technologies is expected to receive substantial policy support under the national "dual carbon" goals[179]. - The feed-grade benzoic acid project is positioned as a beneficial project for public health, replacing antibiotics in animal feed and promoting food safety[168]. Acquisitions and Investments - The company acquired 100% equity of Huaihua Taitong, which produces key raw materials for its core photoinitiator products, ensuring stable supply[44]. - A strategic acquisition of a local competitor is anticipated to enhance production capacity by 30%[28]. - The company has invested in Tianjiao Radiation, holding a 38.46% stake, to enhance its product offerings in UV monomers[61]. - The company has completed the acquisition of Keli Biological and Jinghong Biological in June 2021, marking a significant step in the strategic layout of the photoresist and semiconductor materials field[172]. Future Outlook - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 10% to 1.32 billion RMB[28]. - The company expects a recovery in 2024, with projected revenue of 339.50 million yuan, returning to levels similar to 2021[200]. - The company anticipates a net profit of 15.58 million yuan in 2024, indicating a strong recovery[200]. - The company is focused on returning to normal operations by 2024, with all production expected to be fully restored[200].

关于参加 2022 年度半导体专场集体业绩说明会 暨现金分红说明会的公告 证券代码：688199 证券简称：久日新材 公告编号：2023-023 天津久日新材料股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 会议线上交流时间：2023 年 5 月 17 日（星期三）下午 14:00-16:00 会议召开方式：视频和线上文字互动 视 频 和 线 上 文 字 互 动 平 台 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （http://roadshow.sseinfo.com/） 投资者可于 2023 年 5 月 16 日（星期二）16:00 前通过邮件、电话等形 式将需要了解和关注的问题提前提供给公司。公司将在文字互动环节对投资者普 遍关注的问题进行回答。 天津久日新材料股份有限公司（以下简称公司）已于 2023 年 4 月 15 日发布 公司《2022 年年度报告》，为便于广大投资者更全面深入地了解公司 2022 年度 经营成果、财务状况、发展理念及现金分红的具体情况，公司参与了由上 ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥265,902,365.16, representing a decrease of 37.14% compared to the same period last year[4] - The net profit attributable to shareholders was a loss of ¥17,849,017.84, a decline of 132.59% year-over-year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was a loss of ¥24,293,284.17, reflecting a decrease of 151.03% compared to the previous year[4] - The net cash flow from operating activities was negative at ¥40,395,654.20, a decline of 207.85% year-over-year[4] - The company attributed the decline in revenue and profit to external market conditions and a decrease in sales prices of photoinitiators, despite a slight increase in sales volume[8] - Net profit for Q1 2023 was a loss of ¥20,798,143.39, compared to a profit of ¥60,206,842.13 in Q1 2022[18] - The company reported a gross profit margin of -5.4% in Q1 2023, compared to 14.0% in Q1 2022[17] - Operating profit for Q1 2023 was a loss of ¥12,368,402.33, compared to a loss of ¥473,781.76 in Q1 2022[30] - Net profit for Q1 2023 was a loss of ¥12,963,550.35, compared to a loss of ¥1,003,382.62 in Q1 2022, indicating a worsening financial performance[30] Research and Development - The total R&D investment amounted to ¥14,621,941.34, which is a decrease of 31.06% compared to the previous year[4] - R&D investment accounted for 5.50% of operating revenue, an increase of 0.49 percentage points year-over-year[5] - Research and development expenses for Q1 2023 were ¥14,621,941.34, a decrease of 30.8% from ¥21,208,575.74 in Q1 2022[17] - Research and development expenses decreased to ¥3,553,060.76 in Q1 2023 from ¥5,092,449.04 in Q1 2022, reflecting a 30.3% reduction[28] Assets and Liabilities - Total assets at the end of the reporting period were ¥4,063,682,545.30, a decrease of 1.03% from the end of the previous year[5] - The company's total assets amounted to CNY 4,063,682,545.30, a decrease from CNY 4,105,789,706.50 at the end of 2022, reflecting a decline of approximately 1.02%[13] - The total current assets decreased to CNY 1,825,154,911.49 from CNY 1,896,250,492.13, indicating a reduction of approximately 3.73%[14] - The company's total liabilities increased to CNY 1,800,000,000.00, reflecting a rise in financial obligations[14] - The company's total liabilities decreased to ¥1,255,835,304.83 in Q1 2023 from ¥1,279,229,157.38 in Q1 2022[16] - Total liabilities reached CNY 1.28 billion, with current liabilities at CNY 930.55 million and non-current liabilities at CNY 348.68 million[38] - The company's total liabilities increased to 472,416,697.09 RMB from 446,077,648.21 RMB, indicating a rise in financial obligations[26] Cash Flow - The net cash flow from operating activities was -40,395,654.20 RMB, a significant decline compared to 37,454,291.96 RMB in the previous year, indicating a negative cash flow trend[22] - Cash flow from operating activities was ¥224,371,631.59 in Q1 2023, down 39.0% from ¥367,953,548.42 in Q1 2022[21] - The net cash flow from financing activities was 73,535,817.62 RMB, down from 148,878,918.15 RMB in the previous year, suggesting a decrease in financing efficiency[23] - The cash flow from investment activities showed a net increase of 60,626,737.18 RMB, a significant improvement from a net outflow of -244,329,279.32 RMB in the previous year[22] - The company achieved cash inflow from investment activities of ¥760,122,843.38 in Q1 2023, compared to ¥284,208,949.98 in Q1 2022[32] Shareholder Information - The number of shares held by the top shareholder, Zhao Guofeng, is 19,771,609, representing 17.78% of the total shares[12] - The company has a share repurchase account holding 2,821,248 shares, accounting for 2.54% of the total share capital[12] - The total equity attributable to shareholders was ¥2,706,190,529.17 in Q1 2023, slightly down from ¥2,722,303,782.74 in Q1 2022[16] - Shareholders' equity totaled CNY 2.83 billion, with retained earnings of CNY 599.70 million[39] Inventory and Current Assets - Inventory levels decreased to CNY 328,494,119.38 from CNY 376,395,490.72, showing a decline of about 12.74%[14] - The company's receivables from accounts increased to CNY 206,480,187.18 from CNY 188,958,277.39, marking a rise of about 9.43%[13] - The company's total current assets were 1,681,516,241.08 RMB, slightly up from 1,672,370,769.20 RMB year-over-year, indicating stable asset management[24] Financial Ratios and Metrics - The weighted average return on net assets was -0.66%, a decrease of 2.64 percentage points compared to the previous year[4] - Basic and diluted earnings per share for Q1 2023 were both -¥0.16, compared to ¥0.51 in Q1 2022[19] - The company reported an investment loss of ¥419,077.07 in Q1 2023, compared to a profit of ¥8,523,345.98 in Q1 2022[18] - The company's financial expenses showed a significant improvement, with a net financial expense of -¥103,604.00 in Q1 2023 compared to ¥1,809,197.88 in Q1 2022[28]

Financial Performance - In 2022, the company achieved operating revenue of CNY 1,410,958,551.74, an increase of 12.66% year-on-year[4] - The net profit attributable to shareholders was CNY 43,347,271.78, a decrease of 73.83% year-on-year[4] - The company's operating revenue for 2022 was approximately ¥1.41 billion, representing a 12.66% increase compared to ¥1.25 billion in 2021[29] - The net profit attributable to shareholders decreased by 73.83% to approximately ¥43.35 million from ¥165.66 million in 2021[29] - The basic earnings per share dropped by 73.86% to ¥0.40 from ¥1.53 in the previous year[30] - The net cash flow from operating activities increased by 97.21% to approximately ¥144.06 million, driven by higher cash receipts from sales and increased tax refunds[31] - The total assets at the end of 2022 were approximately ¥4.11 billion, a 6.29% increase from ¥3.86 billion at the end of 2021[29] - The weighted average return on equity decreased to 1.59% from 6.24% in 2021, indicating a significant decline in profitability[30] - The net profit attributable to shareholders after deducting non-recurring gains and losses fell by 87.14% to approximately ¥16.22 million from ¥126.17 million in 2021[29] - The company's gross profit margin decreased by 9.03 percentage points, with a gross profit margin of 18.52%[123] Production and Capacity Expansion - The company expanded its production capacity with the launch of a project in Inner Mongolia, targeting an annual output of 9,250 tons of photoinitiators and intermediates[5] - The company initiated a project for a microelectronics photoinitiator with an annual capacity of 600 tons, which began trial production in October 2022[6] - The company has established multiple production bases to ensure stable supply and customer demand for key photoinitiator products, including 184, TPO, and 1173[51] - The company is investing in new production lines to increase the value of its products, such as the feed-grade benzoic acid production line[165] - The company has built modern production bases in Shandong, Jiangsu, Hunan, and Inner Mongolia, enhancing its supply stability and capacity[96] Research and Development - The company added 52 new authorized patents during the reporting period, including 25 invention patents and 27 utility model patents, enhancing its innovation capabilities[42] - Research and development investments increased by 40%, totaling RMB 100 million, focusing on advanced photoinitiators[21] - The total R&D investment for the year was approximately ¥84.52 million, representing a 19.45% increase from the previous year's ¥70.76 million[79] - R&D investment accounted for 5.99% of total revenue, an increase of 0.34 percentage points compared to the previous year[79] - The company has established a strong R&D foundation with 136 patents, including 89 invention patents[91] - The company is focusing on sustainable development through the improvement of waste treatment processes in its production operations[75] Market Strategy and Challenges - The company aims to maintain its market share by implementing sales strategies, including price reductions, despite the impact on revenue and profit margins[11] - The company has faced challenges due to a significant decline in market demand, leading to a reduction in sales volume of photoinitiators compared to the previous year[11] - The company is actively expanding its market presence and enhancing its competitive advantage through strategic acquisitions and new product development[96] - The company is facing risks of continued performance decline if external market conditions do not improve, despite a gradual recovery in the industry[101] - The company is exposed to foreign exchange risks, particularly with fluctuations in the RMB to USD exchange rate affecting export revenues[106] Environmental and Regulatory Factors - The demand for UV-curable products is expected to increase due to stricter environmental regulations and consumer preferences for safer products[57] - The company is well-positioned to benefit from favorable policies related to energy conservation and emissions reduction in the context of the national "dual carbon" goals[150] - The company has implemented innovative production processes that significantly reduce raw material consumption and waste generation, achieving near-zero wastewater production[155] Acquisitions and Investments - The company acquired 100% equity of Huaihua Taitong, which produces key raw materials for its core photoinitiator products, ensuring stable supply[44] - The company made significant acquisitions, including Hunan Jiuri's purchase of Hongrun Chemical and Huaihua Taitong, contributing to revenue growth[120] - The company plans to invest an additional 31,332.02 million RMB in the Inner Mongolia Jiuri project, increasing the total investment from 55,045.70 million RMB to 86,377.72 million RMB[181] Product Development and Innovation - The company is focused on continuous product development and expanding application areas to drive future growth[56] - The company has developed new core technologies including "photo-sensitizer production technology" and "panel photoresist formulation technology" during the reporting period[69] - The company has successfully developed new photoinitiators tailored for specific applications, enhancing its product offerings[156] Financial Management and Performance Metrics - The company has implemented measures to mitigate production stoppages due to environmental and safety regulations, but risks remain from external factors[111] - The company has experienced a significant decrease in financial expenses by 71.90%, mainly due to exchange rate fluctuations[137] - The company's cash flow from financing activities was CNY 153,278,949.19, compared to a negative cash flow of CNY -50,343,272.44 in the previous year, indicating a significant improvement[138]

2022 年第三季度报告 一、 主要财务数据 （一）主要会计数据和财务指标 证券代码：688199 证券简称：久日新材 天津久日新材料股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中 财务信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期 比上年同 | 年初至报告期末 | 年初至报告期 末比上年同期 | | --- | --- | --- | --- | --- | | | | 期增减变 | | 增减变动幅度 | | | | 动幅度(%) | | (%) | | 营业收入 | 294,205,168.22 | 10.79 | 1,111,657,404.72 | 24.3 ...

Financial Performance - The company reported a significant increase in revenue, achieving a total of 500 million RMB for the first half of 2022, representing a 20% year-over-year growth[13]. - The company's operating revenue for the first half of 2022 was approximately ¥817.45 million, an increase of 30.02% compared to ¥628.70 million in the same period last year[20]. - The net profit attributable to shareholders for the first half of 2022 was approximately ¥99.88 million, representing a 19.38% increase from ¥83.66 million in the previous year[20]. - The basic earnings per share for the first half of 2022 was ¥0.92, up 19.48% from ¥0.77 in the same period last year[19]. - The net cash flow from operating activities increased by 88.56% to approximately ¥130.72 million, compared to ¥69.33 million in the previous year[20]. - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 47.03% to approximately ¥83.67 million, compared to ¥56.91 million in the same period last year[20]. - The company's total assets as of the end of the reporting period were approximately ¥4.40 billion, a 13.80% increase from ¥3.86 billion at the end of the previous year[20]. - The company has maintained a strong cash position, with cash reserves amounting to 200 million RMB, ensuring liquidity for future investments[13]. Research and Development - The company is investing 30 million RMB in R&D for new technologies aimed at improving production efficiency by 15%[13]. - The company's R&D investment accounted for 5.59% of operating revenue, an increase of 0.22 percentage points from the previous year[19]. - The company achieved a total R&D investment of ¥45,659,094.27, representing a 35.16% increase compared to ¥33,780,917.25 in the same period last year[58]. - The company added 39 new authorized patents during the reporting period, including 15 invention patents and 24 utility model patents, enhancing its innovation capabilities[76]. - The company holds 123 patents, including 79 invention patents and 44 utility model patents, and has participated in the formulation of 9 industry standards[67]. - The company has a strong focus on R&D, holding 79 invention patents and 44 utility model patents, enhancing its innovation capabilities[32]. - The company is actively exploring new product developments, including high-performance UV monomers and low-odor photoinitiators, to cater to diverse customer needs[34]. Market Expansion and Strategy - The company is expanding its market presence, targeting new regions in Southeast Asia, with an investment of 50 million RMB allocated for market entry strategies[13]. - A strategic acquisition of a local competitor is in progress, which is projected to enhance market share by 10%[13]. - The company has acquired subsidiaries Hunan Jiuri and Hongrun Chemical, contributing to the increase in consolidated revenue[20]. - The company is adapting to market demands by developing customized photoinitiators that meet the specific needs of downstream customers[41]. - The company is focusing on the development of UV LED photoinitiators suitable for light-colored inks and wood coatings, which are characterized by excellent performance and cost-effectiveness[53]. - The company is expanding its market presence through strategic acquisitions and investments in new technologies and products[116]. Environmental Compliance and Sustainability - The company has implemented various pollution prevention measures, including clean production and wastewater separation systems, to reduce pollutant emissions[129]. - The company has established emergency response plans for environmental incidents to prevent soil contamination[129]. - The company has optimized its VOCs emission treatment systems, including RTO incineration systems, to ensure compliance with emission standards[130]. - The company’s wastewater treatment systems, including physical and biological treatment, are operating normally and meet discharge standards[130]. - The company has implemented strict compliance with environmental laws and regulations across all operational sites[131]. - The company has invested significantly in environmental protection facilities and technology improvements to comply with environmental regulations, which may increase operational costs if stricter regulations are implemented in the future[86]. Risk Management - The management highlighted potential risks, including supply chain disruptions that could impact production capacity by up to 20%[4]. - The company faces risks related to core competitiveness, operational management, and industry competition due to rapid market changes[79][80][81]. - The company faces risks related to the loss of core technical personnel, which could negatively impact operational performance if competitive compensation and incentives are not maintained[89]. - The ongoing impact of the COVID-19 pandemic continues to create uncertainty in demand due to inflation and geopolitical factors[92]. - The company has encountered risks related to the implementation of fundraising investment projects, which are crucial for enhancing competitiveness but face market uncertainties[93]. Shareholder Commitments and Governance - The company commits to strict compliance with laws and regulations to ensure effective governance and protect minority shareholders' rights[184]. - The company will publicly disclose any failure to fulfill commitments and apologize to shareholders, ensuring accountability for any losses incurred[192]. - The company will not engage in unfair practices that harm its interests or those of its shareholders[187]. - The company will adhere to a profit distribution policy as outlined in its articles of association and future shareholder return plans[188]. - The company publicly apologized to shareholders and investors for not fulfilling commitments during the shareholder meeting and on designated media[196].